PLGA-hucMSC-Ex Ameliorates Colitis by Reversing Epithelial-mesenchymal Transition

References

1. Pan B.T. Johnstone R.M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor. Cell 1983 33 3 967 978 10.1016/0092‑8674(83)90040‑5
   [Google Scholar]
2. Harding C. Heuser J. Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 1983 97 2 329 339 10.1083/jcb.97.2.329 6309857
   [Google Scholar]
3. Kalluri R. LeBleu V. The biology, function, and biomedical applications of exosomes. Science 2020 367 6478 eaau6977 10.1126/science.aau6977 32029601
   [Google Scholar]
4. Ocansey D.K.W. Zhang L. Wang Y. Yan Y. Qian H. Zhang X. Xu W. Mao F. Exosome‐mediated effects and applications in inflammatory bowel disease. Biol. Rev. Camb. Philos. Soc. 2020 95 5 1287 1307 10.1111/brv.12608
   [Google Scholar]
5. Xie Q. Liu R. Jiang J. Peng J. Yang C. Zhang W. Wang S. Song J. What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment? Stem Cell Res. Ther. 2020 11 1 519 10.1186/s13287‑020‑02011‑z
   [Google Scholar]
6. Pan X. Li Q. Zhu X. Li Z. Cai X. Pang R. Ruan G. Mechanism and therapeutic effect of umbilical cord mesenchymal stem cells in inflammatory bowel disease. Sci. Rep. 2019 9 1 17646 10.1038/s41598‑019‑54194‑y
   [Google Scholar]
7. Qi L. Wu J. Zhu S. Wang X. Lv X. Liu C. Liu Y.J. Chen J. Mesenchymal stem cells alleviate inflammatory bowel disease via tr1 cells. Stem Cell Rev. Rep. 2022 18 7 2444 2457 10.1007/s12015‑022‑10353‑9
   [Google Scholar]
8. Wei Z. Hang S. Wiredu Ocansey D.K. Zhang Z. Wang B. Zhang X. Mao F. Human umbilical cord mesenchymal stem cells derived exosome shuttling mir-129-5p attenuates inflammatory bowel disease by inhibiting ferroptosis. J. Nanobiotechnology 2023 21 1 188 10.1186/s12951‑023‑01951‑x
   [Google Scholar]
9. Liang X. Li C. Song J. Liu A. Wang C. Wang W. Kang Y. Sun D. Qian J. Zhang X. HucMSC-Exo promote mucosal healing in experimental colitis by accelerating intestinal stem cells and epithelium regeneration via Wnt signaling pathway. Int. J. Nanomedicine 2023 18 2799 2818 10.2147/IJN.S402179
   [Google Scholar]
10. Liu C. Yan X. Zhang Y. Yang M. Ma Y. Zhang Y. Xu Q. Tu K. Zhang M. Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy. J. Nanobiotechnology 2022 20 1 206 10.1186/s12951‑022‑01421‑w
    [Google Scholar]
11. Timofeeva A. Paramonik A. Sedykh S. Nevinsky G. Milk exosomes: Next-generation agents for delivery of anticancer drugs and therapeutic nucleic acids. Int. J. Mol. Sci. 2023 24 12 10194 10.3390/ijms241210194
    [Google Scholar]
12. Danhier F. Ansorena E. Silva J. Coco R. Le Breton A. Préat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release 2012 161 2 505 522 10.1016/j.jconrel.2012.01.043 22353619
    [Google Scholar]
13. Tang J. Li T. Xiong X. Yang Q. Su Z. Zheng M. Chen Q. Colchicine delivered by a novel nanoparticle platform alleviates atherosclerosis by targeted inhibition of NF-κB/NLRP3 pathways in inflammatory endothelial cells. J. Nanobiotechnology 2023 21 1 460 10.1186/s12951‑023‑02228‑z
    [Google Scholar]
14. Yang M. Zhang F. Yang C. Wang L. Sung J. Garg P. Zhang M. Merlin D. Oral targeted delivery by nanoparticles enhances efficacy of an Hsp90 inhibitor by reducing systemic exposure in murine models of colitis and colitis-associated cancer. J. Crohn’s Colitis 2020 14 1 130 141 10.1093/ecco‑jcc/jjz113
    [Google Scholar]
15. Bao W.L. Wu Q. Hu B. Sun D. Zhao S. Shen X. Cheng H. Shen W. Oral nanoparticles of SNX10-shRNA plasmids ameliorate mouse colitis. Int. J. Nanomedicine 2021 16 345 357 10.2147/IJN.S286392
    [Google Scholar]
16. Xie J. Hu Y. Su W. Chen S. Wang J. Liang S. Chen M. Wang H. Ma T. PLGA nanoparticles engineering extracellular vesicles from human umbilical cord mesenchymal stem cells ameliorates polyethylene particles induced periprosthetic osteolysis. J. Nanobiotechnology 2023 21 1 398 10.1186/s12951‑023‑02177‑7
    [Google Scholar]
17. Kang Y. Xu C. Meng L. Dong X. Qi M. Jiang D. Exosome-functionalized magnesium-organic framework-based scaffolds with osteogenic, angiogenic and anti-inflammatory properties for accelerated bone regeneration. Bioact. Mater. 2022 18 26 41 10.1016/j.bioactmat.2022.02.012
    [Google Scholar]
18. Yang J. Antin P. Berx G. Blanpain C. Brabletz T. Bronner M. Campbell K. Cano A. Casanova J. Christofori G. Dedhar S. Derynck R. Ford H.L. Fuxe J. García de Herreros A. Goodall G.J. Hadjantonakis A.K. Huang R.Y.J. Kalcheim C. Kalluri R. Kang Y. Khew-Goodall Y. Levine H. Liu J. Longmore G.D. Mani S.A. Massagué J. Mayor R. McClay D. Mostov K.E. Newgreen D.F. Nieto M.A. Puisieux A. Runyan R. Savagner P. Stanger B. Stemmler M.P. Takahashi Y. Takeichi M. Theveneau E. Thiery J.P. Thompson E.W. Weinberg R.A. Williams E.D. Xing J. Zhou B.P. Sheng G. Guidelines and definitions for research on epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2020 21 6 341 352 10.1038/s41580‑020‑0237‑9
    [Google Scholar]
19. Zhang N. Ng A.S. Cai S. Li Q. Yang L. Kerr D. Novel therapeutic strategies: Targeting epithelial–mesenchymal transition in colorectal cancer. Lancet Oncol. 2021 22 8 e358 e368 10.1016/S1470‑2045(21)00343‑0
    [Google Scholar]
20. Lovisa S. Genovese G. Danese S. Role of epithelial-to-mesenchymal transition in inflammatory bowel disease. J. Crohn’s Colitis 2019 13 5 659 668 10.1093/ecco‑jcc/jjy201
    [Google Scholar]
21. Wang G. Yuan J. Cai X. Xu Z. Wang J. Ocansey D.K.W. Yan Y. Qian H. Zhang X. Xu W. Mao F. HucMSC-exosomes carrying miR-326 inhibit neddylation to relieve inflammatory bowel disease in mice. Clin. Transl. Med. 2020 10 2 e113 10.1002/ctm2.113 32564521
    [Google Scholar]
22. Zhong J. Xia B. Shan S. Zheng A. Zhang S. Chen J. Liang X.J. High-quality milk exosomes as oral drug delivery system. Biomaterials 2021 277 121126 10.1016/j.biomaterials.2021.121126
    [Google Scholar]
23. Philippart M. Schmidt J. Bittner B. Oral delivery of therapeutic proteins and peptides: An overview of current technologies and recommendations for bridging from approved intravenous or subcutaneous administration to novel oral regimens. Drug Res. 2016 66 3 113 120 10.1055/s‑0035‑1564102
    [Google Scholar]
24. Wang L. Li S. Luo H. Lu Q. Yu S. A comprehensive study on the role of metabolic pathways in cancer therapy. J. Exp. Clin. Cancer Res. 2022 41 303 10.1186/s13046‑022‑02535‑4
    [Google Scholar]
25. Zhou X. Han J. Zuo A. THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1- mediat ed PI3K/AKT activation in colorectal cancer. Mol Cancer 2024 23 1 282 10.1186/s12943‑024‑02180‑y
    [Google Scholar]